Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07135596 · ClinicalTrials.gov registry record · NA
Effectiveness and Safety of OviTex® PRS in Breast Reconstruction
A NA study, sponsored by Tela Bio.
- Recruiting
- Registry status
- NA
- Development phase
- 235
- Enrollment target
NCT07135596: Recruiting NA study, sponsored by Tela Bio.
NCT07135596 is a NA study that is actively recruiting participants, run by Tela Bio. The registered enrollment target is 235 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07135596, a NA study, is actively recruiting participants, sponsored by Tela Bio.
- RECRUITING
- Registry status
- NA
- Development phase
- 235 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of OviTex PRS in subjects undergoing implant-based breast reconstruction.
Interventions
- DEVICE OviTex PRS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 235 participants |
| Start Date | 2026-04-10 |
| Est. Completion | 2034-06 |
| Phase | NA |
What NCT07135596 shows while recruiting
NCT07135596 is an interventional study that assigns participants to a tested intervention. The registered 235 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 1 intervention - of which OviTex PRS is the first listed.
NCT07135596 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07135596 about?
NCT07135596 is a clinical study titled "Effectiveness and Safety of OviTex® PRS in Breast Reconstruction". The purpose of this study is to evaluate the safety and effectiveness of OviTex PRS in subjects undergoing implant-based breast reconstruction.
What is the current status of trial NCT07135596?
This trial is currently recruiting. It is a NA study. The enrollment target is 235 participants. The study started on 2026-04-10. Estimated completion is 2034-06.
What interventions are being tested in trial NCT07135596?
The interventions under investigation include: OviTex PRS (DEVICE).
Who is sponsoring clinical trial NCT07135596?
This trial is sponsored by Tela Bio, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07135596's enrollment target sits among peer trials
235 461st of 2000 higher than 1,539 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01524211 · 235 participants · NA
Evaluation of Branch Endografts in the Treatment of Aortic Aneurysms
- NCT05316155 · 235 participants · Phase 1
Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
- NCT05353569 · 235 participants · NA
Coherent Optical Detection of Middle Ear Disease
- NCT05390918 · 235 participants · NA
Targeting Adolescent Insomnia to Lessen Overall Risk of Suicidal Behavior
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI